ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20570925.
- Also identified by DOI 10.1158/1078-0432.CCR-10-1059.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.
Medical subject headings
- ADAM Proteins
- Colorectal Neoplasms